Treatment of Malignant Renal Tumor With Intra-Arterial Administration of Oily Anticancer Drugs

Konno, Shigeru; Tanaka, Junichiroh; Urabe, Daisaku; Miyazaki, Fumio; Noda, Shinshi; Maeda, Hiroshi; Konno, Toshimitsu

doi:10.5980/jpnjurol1928.75.12_1874

Cited by 1 publication

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, there is a demand for a treatment which has a less liver -and general toxicity or systemic side effect, in addition to the local anticancer effect. Targeting therapies, using a microcapsule, fat, and lipiodol methods have recently improved (Audisio et al, 1990;Gregoriadis, 1977;Kato, 1983;Kato et al, 1980Kato et al, , 1984Konno et al, 1983Konno et al, , 1984Widder et al, 1979). These methods were made possible by primary targeting through the nutrient artery of the tumour and complete secondary targeting by adding the embolisation effect.…”

Section: Rabbit Studymentioning

confidence: 99%

“…Anticancer drugs, however, have a very low therapeutic index because of their strong cytotoxicity and the large dosage required to produce the desired effect. To overcome these problems, targeting chemotherapy with drug-carrier complexes was invented, using a microcapsule (Kato et al, 1980), fat (Takahashi et al, 1973), carbon (Hagiwara et al, 1987), dextran (Hashida et al, 1981), and lipiodol (Konno et al, 1983(Konno et al, , 1984.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Implantation treatment method of slow release anticancer doxorubicin containing hydroxyapatite (DOX-HAP) complex. A basic study of a new treatment for hepatic cancer

Kunieda

Seki²,

Nakatani³

et al. 1993

Br J Cancer

View full text Add to dashboard Cite

Summary We performed an experimental study on slow releasing anticancer drug implantation treatment as a new therapy for hepatocellular carcinoma. Hydroxyapatite (HAP) was chosen for the carrier material and doxorubicin hydrochloride (DOX) for anticancer agent. DOX-HAP was produced by adsorbing DOX to porous HAP particles of 1375 ± 125 gm diameter using the freeze drying method. In vitro experiments showed slow release of the drug resulting in the steady release of DOX from HAP for I month duration. In healthy white rabbits with DOX-HAP implantation in the liver, serum DOX was not detectable, and DOX release rate was stable at the implanted region after 7, 14, and 21 days. When DOX-HAP (DOX; 100mg kg-') was administered to mice with sarcoma 180, an improved survival rate was observed without acute toxicity.We also found that VX2 liver tumour growth on white rabbit was inhibited by implantation of DOX-HAP, without acute toxicity. We hope that DOX-HAP implantation therapy will open up new avenues for the treatment of hepatoma.

show abstract